Literature DB >> 3093589

Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients.

C Verhagen, B E de Pauw, J P Donnelly, K J Williams, T de Witte, T H Janssen.   

Abstract

Twenty-nine patients with primary or secondary hypoplastic bone-marrow were treated successfully with ceftazidime alone for established septicaemia caused by Pseudomonas aeruginosa of which 38% strains were gentamicin-resistant . All the patients were neutropenic at the start of therapy; most were cured with microbiological confirmation before the bone marrow had regenerated. One patient died of cerebral haemorrhage due to profound thrombocytopenia without evidence of infection at autopsy. Significant toxicity was not observed. Ceftazidime alone is, therefore, a safe and effective treatment for infections caused by this organism even in the neutropenic patient.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093589     DOI: 10.1016/s0163-4453(86)92813-6

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.

Authors:  E Ulrich; M Trautmann; B Krause; A Bauernfeind; H Hahn
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

2.  Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.

Authors:  I R Nováková; J P Donnelly; B E de Pauw
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

3.  Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.

Authors:  R F Jacobs; T S Vats; K A Pappa; S Chaudhary; M Kletzel; D L Becton
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

4.  Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients.

Authors:  I Nováková; J P Donnelly; B De Pauw
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.